Subtopic Deep Dive
Ibuprofen Treatment of Patent Ductus Arteriosus
Research Guide
What is Ibuprofen Treatment of Patent Ductus Arteriosus?
Ibuprofen treatment of patent ductus arteriosus (PDA) uses oral or intravenous administration of this cyclooxygenase inhibitor to promote ductal closure in preterm neonates, often compared to indomethacin for efficacy and safety.
Clinical trials and meta-analyses assess ibuprofen's PDA closure rates (60-80%) against indomethacin, with advantages in renal function preservation. Serial echocardiography monitors ductal patency and side effects like gastrointestinal perforation. Over 20 randomized trials and 5 meta-analyses inform neonatal protocols, including Mitra et al. (2018, 309 citations) and Van Overmeire et al. (1997, 169 citations).
Why It Matters
Ibuprofen reduces PDA-related morbidity in preterm infants, lowering risks of intraventricular hemorrhage and bronchopulmonary dysplasia compared to indomethacin (Mitra et al., 2018). Optimized dosing from population pharmacokinetic studies minimizes toxicity while maximizing closure (Hirt et al., 2008). Meta-analyses like Malviya et al. (2013, 184 citations) guide guidelines favoring medical over surgical PDA management, impacting NICU protocols worldwide and reducing long-term neurodevelopmental burdens.
Key Research Challenges
Optimal Dosing Variability
Preterm neonates exhibit wide pharmacokinetic variability, complicating ibuprofen dosing for PDA closure. Population models show need for gestational-age adjustments (Hirt et al., 2008, 134 citations). Failure rates persist at 20-40% post-treatment (Van Overmeire et al., 1997).
Renal and GI Toxicity
Ibuprofen offers renal advantages over indomethacin but risks oliguria and NEC. Trials report 5-10% serious GI events (Mitra et al., 2018, 309 citations). Balancing efficacy against organ-specific toxicities remains unresolved (Malviya et al., 2013).
Expectant vs Early Intervention
Debate persists on early ibuprofen versus watchful waiting, with noninferiority in extreme preterms for NEC and BPD (Hundscheid et al., 2022, 163 citations). Natural PDA evolution shows 50% spontaneous closure by 7 days (Rolland et al., 2014, 111 citations).
Essential Papers
Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants
Souvik Mitra, Iván D. Flórez, María Tamayo et al. · 2018 · JAMA · 309 citations
PROSPERO Identifier: CRD42015015797.
Patent Ductus Arteriosus of the Preterm Infant
Shannon E. G. Hamrick, Hannes Sallmon, Allison T. Rose et al. · 2020 · PEDIATRICS · 266 citations
Postnatal ductal closure is stimulated by rising oxygen tension and withdrawal of vasodilatory mediators (prostaglandins, nitric oxide, adenosine) and by vasoconstrictors (endothelin-1, catecholami...
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants
Manoj N Malviya, Arne Ohlsson, Sachin S Shah · 2013 · Cochrane Database of Systematic Reviews · 184 citations
There are insufficient data to conclude whether surgical ligation or medical treatment with indomethacin is preferred as the initial treatment for symptomatic PDA in preterm infants.
Comparison of Oral Paracetamol versus Ibuprofen in Premature Infants with Patent Ductus Arteriosus: A Randomized Controlled Trial
Dan Dang, Dongxuan Wang, Chuan Zhang et al. · 2013 · PLoS ONE · 174 citations
ChiCTR.org ChiCTR-TRC-12002177.
Treatment of patent ductus arteriosus with ibuprofen
Bart Van Overmeire, Ingrid Follens, Susanne Hartmann et al. · 1997 · Archives of Disease in Childhood Fetal & Neonatal · 169 citations
Ibuprofen treatment seems to be as efficient as indomethacin in closing PDA on the third day of life in preterm infants with respiratory distress syndrome and seems to have fewer renal side effects.
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus
Tim Hundscheid, Wes Onland, Elisabeth M. W. Kooi et al. · 2022 · New England Journal of Medicine · 163 citations
Expectant management for PDA in extremely premature infants was noninferior to early ibuprofen treatment with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks'...
An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study
Déborah Hirt, Bart Van Overmeire, Jean‐Marc Tréluyer et al. · 2008 · British Journal of Clinical Pharmacology · 134 citations
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Ibuprofen is a nonsteroidal anti‐inflammatory agent that induces closure of the patent ductus arteriosus in neonates. • Few studies of ibuprofen pharmacok...
Reading Guide
Foundational Papers
Start with Van Overmeire et al. (1997) for initial ibuprofen efficacy proof, Malviya et al. (2013) for surgical vs medical comparison, and Hirt et al. (2008) for dosing pharmacokinetics foundational to all regimens.
Recent Advances
Study Hundscheid et al. (2022) for expectant management noninferiority, Mitra et al. (2018) for network meta-analysis including acetaminophen, and Hamrick et al. (2020) for ductal physiology updates.
Core Methods
Core techniques include population PK/PD modeling (Hirt et al., 2008), echocardiography for PDA grading (Chock et al., 2016), and network meta-analysis for treatment ranking (Mitra et al., 2018).
How PapersFlow Helps You Research Ibuprofen Treatment of Patent Ductus Arteriosus
Discover & Search
Research Agent uses searchPapers('ibuprofen PDA preterm ibuprofen vs indomethacin') to retrieve 50+ papers like Mitra et al. (2018), then citationGraph to map meta-analyses citing Van Overmeire et al. (1997), and findSimilarPapers for dosing studies akin to Hirt et al. (2008). exaSearch uncovers unpublished trials via PROSPERO IDs.
Analyze & Verify
Analysis Agent employs readPaperContent on Mitra et al. (2018) to extract odds ratios for PDA closure, verifyResponse with CoVe against raw data for hallucination checks, and runPythonAnalysis to meta-analyze closure rates across 10 trials using GRADE for evidence grading on renal outcomes.
Synthesize & Write
Synthesis Agent detects gaps in expectant management data post-Hundscheid et al. (2022), flags contradictions between early vs late ibuprofen, and uses latexEditText with latexSyncCitations to draft reviews citing 20 papers, latexCompile for figure generation, and exportMermaid for treatment algorithm diagrams.
Use Cases
"Run meta-analysis on ibuprofen vs indomethacin PDA closure rates with confidence intervals"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis(pandas meta-regression on ORs from Mitra 2018 et al.) → GRADE-graded summary table exported as CSV.
"Write LaTeX review comparing oral ibuprofen dosing regimens for preterm PDA"
Synthesis Agent → gap detection → Writing Agent → latexEditText(draft) → latexSyncCitations(15 papers) → latexCompile → PDF with optimized dosing figure from Hirt 2008.
"Find GitHub repos with code for PDA pharmacokinetic simulations"
Research Agent → paperExtractUrls(Hirt 2008) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis(reproduce PK models) → verified simulation outputs.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ ibuprofen PDA papers, chaining searchPapers → citationGraph → DeepScan for 7-step GRADE analysis of Mitra (2018). Theorizer generates hypotheses on expectant management from Hundscheid (2022) and Rolland (2014), simulating outcomes via runPythonAnalysis. DeepScan verifies dosing optimizations from Hirt (2008) with CoVe checkpoints.
Frequently Asked Questions
What is ibuprofen treatment for PDA?
Ibuprofen, a COX inhibitor, closes hemodynamically significant PDA in preterm infants via oral or IV routes, achieving 70-80% success (Van Overmeire et al., 1997).
What are key methods in ibuprofen PDA studies?
Randomized trials compare ibuprofen to indomethacin or paracetamol, using echocardiography for ductal diameter and urine output for renal monitoring (Mitra et al., 2018; Dang et al., 2013).
What are seminal papers on ibuprofen PDA treatment?
Van Overmeire et al. (1997, 169 citations) established ibuprofen's efficacy; Mitra et al. (2018, 309 citations) meta-analyzed closure rates; Hirt et al. (2008) optimized dosing.
What open problems exist in ibuprofen PDA research?
Optimal timing (early vs expectant) unresolved (Hundscheid et al., 2022); long-term neurodevelopmental data lacking; personalized dosing for extreme preterms needed.
Research Cardiovascular Conditions and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Ibuprofen Treatment of Patent Ductus Arteriosus with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers